Yoshihide Sehara

Yoshihide Sehara

Auto-generated profile, based on publicly available information

Yoshihide Sehara

Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in World Neurosurgery
Verified
Journal Article
Closed access
NKNaoki Kaneko
Naoki Kaneko
HUHenrik Ullman
Henrik Ullman
FAFadil Ali
Fadil Ali
PBPhilipp Berg
Philipp Berg
YOYinn Cher Ooi
Yinn Cher Ooi
RJReza Jahan
Reza Jahan

25 September 2018 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
YSYoshihide Sehara
Yoshihide Sehara
TIToshiki Inaba
Toshiki Inaba
TUTakao Urabe
Takao Urabe
FKFumio Kurosaki
Fumio Kurosaki
MUMasashi Urabe
Masashi Urabe
HMHiroaki Mizukami
Hiroaki Mizukami

30 June 2023 in The Journal of Gene Medicine
Verified
Journal Article
Open access
YHYuka Hayashi
Yuka Hayashi
YSYoshihide Sehara
Yoshihide Sehara
RWRyota Watano
Ryota Watano
KOKenji Ohba
Kenji Ohba
YTYuki Takayanagi
Yuki Takayanagi
HMHiroaki Mizukami
Hiroaki Mizukami
Background: Fabry disease (FD) is an inherited lysosomal storage disease caused by deficiency of α‐galactosidase A (α‐Gal A) encoded by the GLA gene. The symptoms of FD occur as a result of the accumulation of globotriaosylceramide (Gb3), comprising a substrate of α‐Gal A, in the organs. Adeno‐associated virus (AAV)‐mediated gene therapy is a promising treatment for FD.Methods: α‐Gal A knockout (GLAko) mice were injected intravenously with AAV2 (1 × 1011 viral genomes [vg]) or AAV9 (1 × 1011 or 2 × 1012 vg) vectors carrying human GLA (AAV‐hGLA), and plasma, brain, heart, liver and kidney were tested for α‐Gal A activity. The vector genome copy numbers (VGCNs) and Gb3 content in each organ were also examined.Results: The plasma α‐Gal A enzymatic activity was three‐fold higher in the AAV9 2 × 1012 vg group than wild‐type (WT) controls, which was maintained for up to 8 weeks after injection. In the AAV9 2 × 1012 vg group, the level of α‐Gal A expression was high in the heart and liver, intermediate in the kidney, and low in the brain. VGCNs in the all organs of the AAV9 2 × 1012 vg group significantly increased compared to the phosphate‐buffered‐saline (PBS) group. Although Gb3 in the heart, liver and kidney of the AAV9 2 × 1012 vg was reduced compared to PBS group and AAV2 group, and the amount of Gb3 in the brain was not reduced.Conclusions: Systemic injection of AAV9‐hGLA resulted in α‐Gal A expression and Gb3 reduction in the organs of GLAko mice. To expect a higher expression of α‐Gal A in the brain, the injection dosage, administration route and the timing of injection should be reconsidered.

1 March 2024 in Human Gene Therapy
Verified
Journal Article
Closed access
YHYuka Hayashi
Yuka Hayashi
YSYoshihide Sehara
Yoshihide Sehara
RWRyota Watano
Ryota Watano
KOKenji Ohba
Kenji Ohba
YTYuki Takayanagi
Yuki Takayanagi
HMHiroaki Mizukami
Hiroaki Mizukami
Fabry disease (FD) is an inherited lysosomal storage disease caused by deficiency of α-galactosidase A (α-Gal A), an enzyme that hydrolyzes glycosphingolipids in lysosome. Accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3) in tissues induces cellular dysfunction leading to multi-organ disorder. Gene therapy is a promising strategy that can overcome these problems, and virus vectors such as adeno-associated virus (AAV) have been used for study on gene therapy. We used human Gb3 synthetase-transgenic (TgG3S)/α-Gal A knockout (GLAko) mice. TgG3S/GLAko mice have elevated Gb3 accumulation in the major organs compared to GLAko mice, which have been widely used as a model for FD. At the age of 6 weeks, male TgG3S/GLAko were injected with 2 × 1012 vector genome AAV9 vectors containing human α-Gal A cDNA. Eight weeks after intravenous injection of AAV, α-Gal A enzymatic activity was elevated in the plasma, heart, and liver of TgG3S/GLAko mice to levels corresponding to 224%, 293%, and 105% of wild-type (WT), respectively. Gb3 amount 8 weeks after AAV injection in the heart and liver of this group was successfully reduced to levels corresponding to 16% and 3% of untreated TgG3S/GLAko mice. Although the brain and kidney of AAV9-treated TgG3S/GLAko mice showed no significant increases in α-Gal A activity, Gb3 amount was smaller than untreated littermates (48% and 44%, respectively). In this study, systemic AAV administration did not show significant extension of the lifespan of TgG3S/GLAko mice compared to the untreated littermates. The timing of AAV injection, capsid choice, administration route, and injection may be important to achieve sufficient expression of α-Gal A in the whole body for the amelioration of lifespan.

17 January 2022 in Human Gene Therapy
Verified
Journal Article
Closed access
YSYoshihide Sehara
Yoshihide Sehara
YHYuka Hayashi
Yuka Hayashi
KOKenji Ohba
Kenji Ohba
RURyosuke Uchibori
Ryosuke Uchibori
MUMasashi Urabe
Masashi Urabe
HMHiroaki Mizukami
Hiroaki Mizukami
The safety and high efficiency of adeno-associated virus (AAV) vectors has facilitated their wide-scale use to deliver therapeutic genes for experimental and clinical purposes in diseases affecting the central nervous system (CNS). AAV1, 2, 5, 8, 9, and rh10 are the most commonly used serotypes for CNS applications. Most AAVs are known to transduce genes predominantly into neurons. However, the precise tropism of AAVs in the dentate gyrus (DG), the region where persistent neurogenesis occurs in the adult brain, is not fully understood. We stereotaxically injected 1.5 × 10 10 viral genomes of AAV2, 5, or rh10 carrying green fluorescent protein (GFP) into the right side of gerbil hippocampus, and performed immunofluorescent analysis using differentiation stage-specific markers 1 week after injection. We found that AAV5 showed a significantly larger number of double-positive cells for GFP and Sox2 in the DG, compared with the AAV2 and rh10 groups. On the contrary, AAVrh10 presented a substantially larger number of double-positive cells for GFP and NeuN in the DG, compared with AAV2 and AAV5. Our findings indicated that AAV5 showed high transduction efficiency to neural stem cells and precursor cells, whereas AAVrh10 showed much higher efficiency to mature neurons in the DG.

15 November 2020 in Internal Medicine
Verified
Journal Article
Open access
PDF file
YSYoshihide Sehara
Yoshihide Sehara
HYHaruna Yabe
Haruna Yabe
AIAkio Iwanami
Akio Iwanami
NNNobuyuki Nakamura
Nobuyuki Nakamura
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies